HealthDay - THURSDAY, Jan. 24 (HealthDay News) -- A study of the new anti-clotting drug idraparinux for preventing strokes was stopped early because of excess bleeding, a problem that has plagued the medication.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.